Palisade Bio, Inc. (PALI) Stock Score, Valuation & Financial Research

Palisade Bio, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PALI

Palisade Bio, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.59. These figures are a research snapshot, not a buy or sell recommendation.

What Palisade Bio, Inc. does

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing oral therapies for patients with gastrointestinal diseases. The company currently operates as a research and development entity and has not yet generated revenue from product sales, relying instead on capital raises and potential future licensing or collaboration agreements.

Products and services

  • The company is developing PALI-2108, an oral, prodrug therapeutic candidate designed for the treatment of ulcerative colitis and other inflammatory bowel diseases.

Customer types

Healthcare professionals; Third-party payors.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on third-party contract research organizations to conduct clinical trials and preclinical studies. Source
  • Contract Manufacturing Organizations (CMOs) — The company utilizes third-party contract manufacturing organizations for the production of clinical trial materials. Source

Business strengths to evaluate

  • Proprietary prodrug technology platform Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on the success of a single clinical-stage product candidate Source
  • Requirement for additional capital to fund operations Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PALI financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.59
Market capitalization:
275.99M (currency not supplied)
Revenue:
USD 500K
Net income:
USD -31.94M
Free cash flow:
USD -10.85M
Cash:
USD 125.17M
Total debt:
USD 71K
EPS:
USD -0.53

What stands out

  • Free cash flow is USD -10.85M, negative for the stored period.
  • The balance sheet shows USD 125.17M of cash versus USD 71K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -2169.4% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -6388.2% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 125.1M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PALI

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can PALI fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is PALI likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for PALI to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of PALI's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-12.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research PALI

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.